NNVC
NanoViricides, Inc.
NYSE AmericanUSDEQUITY
DELAYED
Last price
1.34
▲ 0.03 (2.24%)
MARKET · —
Price
Open
1.34
Prev close
1.31
Day high
1.39
Day low
1.31
Volume
249.28K
Market cap
—
P/E (TTM)
—
52W range
0.85 – 2.23
Trailing performance
Returnvs SPY
1W
-3.62%
-2.3%
1M
-13.07%
-16.8%
3M
-14.19%
-17.3%
6M
+30.39%
+19.3%
YTD
+17.70%
+5.4%
1Y
-2.92%
-22.9%
3Y
-0.75%
-74.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.36
-1.23% from price
SMA 20
1.43
-7.12% from price
SMA 50
1.46
-8.88% from price
SMA 100
1.41
-5.28% from price
SMA 200
1.29
+3.10% from price
EMA 12
1.38
-2.62% from price
EMA 26
1.43
-6.23% from price
EMA 50
1.44
-7.31% from price
RSI (14)
39.0
Neutral
MACD (12,26,9)
-0.05
Hist -0.01
ATR (14)
0.08
5.85% of price
Realised vol 30D
57.5%
Annualised
Bollinger upper
1.61
20, 2σ
Bollinger lower
1.25
20, 2σ
50 / 200 cross
Golden
1.46 vs 1.29
Trend bias
Above 200
+3.10%
Risk profile
Beta vs SPY
1.88
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
57.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-58.1%
Peak to trough
Max drawdown 5Y
-86.3%
Peak to trough
ATR 14
0.08
5.85% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
ACCESS Newswire · 4d ago
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
ACCESS Newswire · 12d ago
NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo
MT Newswires · 25d ago
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
ACCESS Newswire · 25d ago
NanoViricides Shares Fall Pre-Bell After $3.8 Million Direct Stock Sale Pricing
MT Newswires · 29d ago
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
ACCESS Newswire · 29d ago
NanoViricides Seeks Approval for Phase 2 Trial of NV-387 Oral Gummies to Treat Ebola in Congo
MT Newswires · 31d ago
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
ACCESS Newswire · 31d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.